Carcinoma Transitional Cell/mortality/surgery Cystectomy Disease-Free Survival Humans Nephroureterectomy Prognosis *Sex Factors Urinary Bladder Neoplasms/*mortality/*surgery Urologic Neoplasms/*mortality/*surgery carcinoma meta-analysis review [publication type] transitional cell urinary bladder neoplasms

Administration Intravesical Antineoplastic Agents/*administration & dosage/adverse effects Clinical Trials as Topic Disease Progression Humans Neoplasm Metastasis *Neoplasm Recurrence Local Network Meta-Analysis Progression-Free Survival Risk Assessment Risk Factors Time Factors Urinary Bladder Neoplasms/*drug therapy/mortality/pathology

*Clinical Protocols *Cystectomy/methods *Enhanced Recovery After Surgery Humans Time Factors Treatment Outcome Urinary Bladder Neoplasms/*surgery Cystectomy Eras Fast track Meta-analysis Protocol Systematic review evidence-based medicine

Carcinoma Transitional Cell/*classification/*genetics/mortality Humans Predictive Value of Tests Survival Rate Treatment Outcome Urinary Bladder Neoplasms/*classification/*genetics/mortality Bladder cancer Molecular classification Molecular subtype Prognosis Progression Urothelial carcinoma

Humans Lymphocytes/*pathology Neutrophils/*pathology *Preoperative Care Prognosis Publication Bias Survival Analysis Urinary Bladder Neoplasms/*immunology/*surgery

Biomarkers Tumor/*analysis Carcinoma Transitional Cell/*chemistry/*drug therapy Humans Neoadjuvant Therapy Prognosis Urinary Bladder Neoplasms/*chemistry/*drug therapy Biomarkers Nac Neoadjuvant systemic therapy Ucb bladder cancer systematic review

Animals Diabetes Mellitus/*physiopathology Disease Progression Humans Obesity/*complications Urinary Bladder Neoplasms/etiology/*pathology all-cause mortality cancer specific mortality diabetes disease recurrence obesity overweight urinary bladder cancer commercial or financial relationships that could be construed as a potential conflict of interest.

Carcinoma Transitional Cell/*drug therapy Humans Prognosis Receptors Fibroblast Growth Factor/*antagonists & inhibitors Urinary Bladder Neoplasms/*drug therapy Bladder cancer Fgfr FGFR inhibitors Fgfr3 Progression Urothelial carcinoma

Carcinoma in Situ/*diagnosis/*therapy Humans Treatment Outcome Urinary Bladder Neoplasms/*diagnosis/*therapy Bladder cancer Carcinoma in situ Non–muscle-invasive bladder cancer

Cystectomy/adverse effects/*methods Disease-Free Survival Follow-Up Studies Humans Incidence Intraoperative Complications/*epidemiology/etiology Length of Stay/statistics & numerical data Neoplasm Recurrence Local/*epidemiology/etiology/prevention & control Randomized Controlled Trials as Topic Urinary Bladder/*injuries/pathology/surgery Urinary Bladder Neoplasms/mortality/pathology/*surgery Bipolar bladder tumors meta-analysis monopolar transurethral resection

Adjuvants Immunologic/*administration & dosage Administration Intravesical BCG Vaccine/*administration & dosage Humans *Lymphocytes Tumor-Infiltrating Treatment Outcome Urinary Bladder Neoplasms/*drug therapy/immunology/*pathology

Urinary bladder neoplasms adjuvant chemotherapy meta-analysis neoadjuvant chemotherapy (NAC) form (available at http://dx.doi.org/10.21037/tau-20-571). Dr. XZ serves as an unpaid editorial board member of Translational Andrology and Urology from Mar 2015 to Feb 2021. The other authors have no conflicts of interest to declare.

Cystectomy/*methods Humans Survival Analysis Urinary Bladder Neoplasms/mortality/*surgery Bladder cancer Delay Radical cystectomy Survival

Cystoscopy/*methods Humans *Microscopy Confocal Urinary Bladder Neoplasms/*pathology Bladder cancer Confocal laser endomicroscopy Diagnostic performance Meta-analysis

Adjuvants Immunologic/administration & dosage Administration Intravesical Antibiotics Antineoplastic/administration & dosage/adverse effects Antimetabolites Antineoplastic/*administration & dosage/adverse effects BCG Vaccine/administration & dosage Bias Cause of Death Confidence Intervals Deoxycytidine/administration & dosage/adverse effects/*analogs & derivatives Disease Progression Drug Administration Schedule Humans Mitomycin/administration & dosage/adverse effects Neoplasm Recurrence Local/*drug therapy/mortality/prevention & control Randomized Controlled Trials as Topic Saline Solution/administration & dosage Urinary Bladder Neoplasms/*drug therapy/mortality/pathology/prevention & control Gemcitabine

Adjuvants Immunologic/therapeutic use BCG Vaccine/therapeutic use Evidence-Based Medicine Humans Neoplasm Invasiveness Neoplasm Recurrence Local/*therapy Treatment Outcome Urinary Bladder Neoplasms/pathology/*therapy Bacillus Calmette-Guerin unresponsive Bladder preservation therapy Bladder sparing Non–muscle-invasive bladder cancer

Aged Cystectomy/adverse effects/*methods/statistics & numerical data Humans Male Middle Aged Postoperative Complications Quality of Life Randomized Controlled Trials as Topic Robotic Surgical Procedures/adverse effects/*methods/statistics & numerical data Treatment Outcome Urinary Bladder Neoplasms/*surgery

Anti-Bacterial Agents/therapeutic use Antibiotic Prophylaxis Humans Meta-Analysis as Topic Postoperative Complications/drug therapy Systematic Reviews as Topic *Urinary Bladder Neoplasms/drug therapy/surgery *Urinary Tract Infections/drug therapy/prevention & control Antibiotic resistance Antibiotics Antimicrobial stewardship Bacteriuria Endourological surgery Guideline Recommendation Transitional cell carcinoma Urothelium cell carcinoma

*Cystectomy/adverse effects Humans Morbidity Postoperative Complications/epidemiology Retrospective Studies *Urinary Bladder Neoplasms/surgery bladder disorders surgery urological tumours

Aged *Diet Dietary Fiber/*administration & dosage Female Humans Male Middle Aged Prospective Studies Risk Factors Urinary Bladder Neoplasms/*prevention & control *Whole Grains bladder cancer cohort study dietary fiber dose-response analysis grain